N/A
Completed N=96
Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Vascular Endothelial Growth Factor Overexpression
Source: ClinicalTrials.gov NCT00848185 ↗
Enrolled (actual)
96
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcomePrimary: VEGF Protein and mRNA Levels — 1395; 1069; 1666 pg/ml — p=<0.001
Summary
Introduction OHSS still remains a complication of assisted reproduction treatments. hCG administration to trigger final oocyte maturation will release vascular mediators, being VEGF and other proteins such as VE-Cadherin or Angiopoietin- 2. It has been shown that replacing hCG by GnRH agonists will induce a very short endogenous LH peak, potent enough to induce final oocyte maturation but no OHSS will develop. The investigators examined VEGF, VE-Cadherin and Angiopoietin-2 modulation by hCG as well as GnRH agonists in oocyte donors undergoing controlled ovarian stimulation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY VEGF Protein and mRNA Levels |
1395; 1069; 1666 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Donors
Exclusion Criteria
- Important diseases
Data sourced from ClinicalTrials.gov (NCT00848185). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.